Correlation Between Alnylam Pharmaceuticals and Halozyme Therapeutics

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Halozyme Therapeutics, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Halozyme Therapeutics.

Diversification Opportunities for Alnylam Pharmaceuticals and Halozyme Therapeutics

-0.08

Correlation Coefficient

Alnylam Pharmaceuticals  Halozyme Therapeutics

Good diversification

The 3 months correlation between Alnylam and Halozyme is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Halozyme Therapeutics go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Halozyme Therapeutics

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 0.79 times more return on investment than Halozyme Therapeutics. However, Alnylam Pharmaceuticals is 1.26 times less risky than Halozyme Therapeutics. It trades about 0.25 of its potential returns per unit of risk. Halozyme Therapeutics is currently generating about -0.05 per unit of risk. If you would invest  27,655  in Alnylam Pharmaceuticals on May 7, 2025 and sell it today you would earn a total of  14,301  from holding Alnylam Pharmaceuticals or generate 51.71% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Halozyme Therapeutics

Alnylam Pharmaceuticals

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Halozyme Therapeutics

Risk-Adjusted Performance

Weakest

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Alnylam Pharmaceuticals and Halozyme Therapeutics

The main advantage of trading using opposite Alnylam Pharmaceuticals and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.

The idea behind Alnylam Pharmaceuticals and Halozyme Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.